1052-P: Investigation of the Extrapancreatic Effects of the DPP-4 Inhibitor Sitagliptin: A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial in Totally Pancreatectomized Patients

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1052-P
Author(s):  
MILLE BAEKDAL ◽  
ASGER LUND ◽  
SOPHIE W. NIELSEN ◽  
CARSTEN HANSEN ◽  
JAN H. STORKHOLM ◽  
...  
Keyword(s):  
Crossover Trial ◽  
Double Blinded ◽  
Extrapancreatic Effects

scholarly journals Double-blinded, placebo-controlled crossover trial to determine the effects of midodrine on blood pressure during cognitive testing in persons with SCI

Spinal Cord ◽  
2020 ◽  
Vol 58 (9) ◽  
pp. 959-969
Author(s):  
Jill M. Wecht ◽  
Joseph P. Weir ◽  
Caitlyn G. Katzelnick ◽  
Nancy D. Chiaravalloti ◽  
Steven C. Kirshblum ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Crossover Trial ◽  
Cognitive Testing ◽  
Double Blinded

scholarly journals A Single Meal of Milk Containing A2 Β-Casein Causes Fewer Symptoms and Lower Gas Production than Milk Containing Both A1 and A2 Β-Casein Among Lactose Intolerant Individuals

2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 772-772
Author(s):  
Monica Ramakrishnan ◽  
Tracy Eaton ◽  
Omer Sermet ◽  
Dennis Savaiano
Keyword(s):  
Hydrogen Production ◽  
Crossover Trial ◽  
Gas Production ◽  
Breath Hydrogen ◽  
Funding Sources ◽  
Randomized Crossover Trial ◽  
Single Meal ◽  
Commercial Milk ◽  
Double Blinded ◽  
Different Levels

Abstract Objectives We evaluated tolerance to single meals of milks containing different levels of a1 and a2 β-casein as compared to lactose-free milk. We also determined if lactose digestion was affected by a2, high a2 (Jersey) and high a1 (commercial) β-casein milks, as measured by breath hydrogen. Methods A double-blinded, randomized crossover trial was conducted in 21 verified lactose intolerant subjects, feeding four milks (commercial, Jersey, a2 and commercial lactose free) after an overnight fast. Breath hydrogen was measured, and intolerance symptoms were recorded for 6 hours following treatment. Results Mean hydrogen production and total symptoms were significantly lower following consumption of a2 milk as compared to commercial milk (P = 0.03 for both). Similarly, high a2 Jersey milk produced significantly lower hydrogen than commercial milk (P = 0.01). However, symptoms due to Jersey were not significantly different from commercial milk (P = 0.47). Conclusions A2 milk caused fewer symptoms and lower gas production in verified lactose intolerant subjects. Funding Sources Gift funds from the a2 Milk Company.

scholarly journals Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial

Nutrients ◽  
2019 ◽  
Vol 11 (3) ◽  
pp. 640 ◽  
Author(s):  
Rebeca Quirós-Fernández ◽  
Bricia López-Plaza ◽  
Laura Bermejo ◽  
Samara Palma-Milla ◽  
Carmen Gómez-Candela
Keyword(s):  
Blood Pressure ◽  
Endothelial Dysfunction ◽  
Endothelial Function ◽  
Crossover Trial ◽  
Adult Population ◽  
Oral Supplementation ◽  
Flow Mediated Dilatation ◽  
Asymptomatic Phase ◽  
Double Blinded ◽  
Early Atherosclerosis

Hydroxytyrosol (HT) and Punicalagin (PC) exert cardioprotective and anti-atherosclerotic effects. This study evaluates the effect of oral supplementation with HT and PC (SAx) on early atherosclerosis markers in middle-aged, seemingly healthy adults. A randomized, double-blinded, placebo-controlled, crossover trial was performed for 20 weeks. There were two treatment sequences (Placebo/SAx, n = 41; SAx/Placebo, n = 43) for which the intervention periods (Placebo and SAx) were 8 weeks long, followed by a 4-week wash out period. The supplement was composed of 9.9 mg of HT and 195 mg of PC, and the placebo was composed of maltodextrin. SAx increased endothelial function (Flow-mediated dilatation [FMD]: 2.36%; p < 0.001) in the endothelial dysfunction subgroup compared to the placebo (2.36 ± 3.9 vs. 0.76 ± 3.5%, p < 0.05). SAx also reduced oxLDL by −28.74 ng/mL (p < 0.05) in subjects with higher levels of oxLDL, which was an improvement compared with the placebo (−28.74 ± 40.2 vs. 25.64 ± 93.8 ng/mL, p < 0.001). The prehypertension and hypertension subgroups exhibited decreased systolic (−15.75 ± 9.9 mmHg; p < 0.001) and diastolic (−6.36 ± 8.7 mmHg; p < 0.001) blood pressure after SAx consumption. Moreover, the systolic prehypertension and hypertension subgroups presented significant differences in systolic blood pressure compared to the placebo (−15.75 ± 9.9 vs. −2.67 ± 12.0 mmHg, p < 0.05). In conclusion, the supplement exerted anti-atherosclerotic effects by improving endothelial function, blood pressure, and levels of circulating oxLDL, especially for persons in whom these parameters were altered.

Sign in / Sign up

Export Citation Format

Share Document